Day One Director Saira Ramasastry Cashs Out All Equity in $21.50/Share Servier Merger

Day One Biopharmaceuticals director Saira Ramasastry exited all her reported equity holdings following the company's cash merger with Servier. This move reflects the standard conversion of insider stock and options into cash at the $21.50 per share acquisition price.

The merger between Day One Biopharmaceuticals and Servier officially concluded on April 23, 2026. This transaction involved Servier acquiring Day One, transforming it into a wholly owned subsidiary. Such cash acquisitions typically require the conversion or cancellation of all outstanding company equity, including shares, options, and restricted stock units, for a predetermined cash value.

Saira Ramasastry, a director for Day One Biopharmaceuticals, disposed of her entire reported equity portfolio in connection with this cash merger. Her holdings included 40,485 shares of common stock, 15,000 restricted stock units (RSUs), and several grants of stock options. These disposals occurred as a direct result of the merger terms.

Each Day One share converted into the right to receive $21.50 in cash upon the merger's completion. For stock options and restricted stock units (RSUs), the company canceled these instruments in exchange for a cash payment. This payment calculated based on the $21.50 per share merger price, deducting any applicable exercise costs for options and relevant taxes.

A regulatory filing, known as a Form 4, documented these equity changes. The Form 4, which publicly reports beneficial ownership of securities by company insiders, confirms Ramasastry holds zero remaining shares or options after these mandatory transactions.

These transactions illustrate the automatic process by which insider equity converts during a corporate cash acquisition. Ramasastry's equity disposition was not a discretionary sale on the open market but a required action dictated by the merger agreement's closing mechanics. It ensured that all Day One shareholders, including directors and other insiders, received the agreed-upon cash value for their ownership stakes, consistent with the deal's structure. Such filings provide transparency on how equity interests are settled following major corporate events.

Stakeholders will now monitor the operational integration of Day One Biopharmaceuticals within Servier and anticipate any subsequent announcements regarding leadership or organizational structure.